Novartis and GARDP partner to accelerate the availability of antibiotics for children

The Global Antibiotic Research and Development Partnership (GARDP; Geneva, Switzerland) has joined forces with Novartis (Basel, Switzerland) to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries.

Currently, infectious diseases, including serious bacterial infections such as pneumonia and sepsis, are leading causes of child morbidity and mortality. However, treatment options for this vulnerable population are limited and rising drug resistance poses a serious concern.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment